rs12551268 — IL33 IL33 asthma-protective variant

IL33 rs12551268 — A Protective Whisper in the Alarmin Switch

Your airways rely on a rapid alarm system. When epithelial cells lining the bronchi are damaged by allergens, viruses, or pollutants, they release a signalling protein called IL-33 (interleukin-33)¹¹ IL-33 (interleukin-33)
An alarmin cytokine released from epithelial cell nuclei upon tissue damage; it binds the ST2 receptor on mast cells, ILC2s, eosinophils, and Th2 cells to initiate type-2 allergic inflammation — the core biology of asthma and hay fever. Several common IL33 variants are known to amplify this signal, raising asthma risk. The rs12551268 A allele appears to work in the opposite direction — a directional protective signal against childhood asthma observed in a Finnish birth cohort, though the effect has not yet reached statistical significance in the one published study.

The Mechanism

rs12551268 sits deep within intron 5 of IL33 on chromosome 9 (GRCh38 chr9:6,231,318), within an intron of the gene rather than in a coding region. The C allele is the common allele (~72% in Europeans), while the A allele is rarer (~28%). Intronic variants in this region of IL33 can influence gene expression by altering regulatory elements²² regulatory elements
DNA sequences within introns that can act as enhancers, silencers, or splice-efficiency regulators, shaping when and how much mRNA is produced from the gene or by modulating alternative splicing efficiency. The A allele may reduce IL33 mRNA output or alter the balance of full-length versus truncated isoforms — a mechanism consistent with the well-characterised protection conferred by the IL33 splice-LOF variant rs146597587³³ rs146597587
A rare splice-acceptor variant in IL33 that produces a truncated, ST2-blind IL-33 protein; carriers have 40% lower IL33 mRNA and are ~50% less likely to develop asthma (OR 0.47 in Smith et al. 2017). The precise functional mechanism of rs12551268 has not been established by experimental studies.

The Evidence

The primary evidence comes from a prospective Finnish birth cohort⁴⁴ prospective Finnish birth cohort
Teräsjärvi et al. 2024, APMIS; 146 children followed from birth to age 7 years; ST2 and IL-33 polymorphisms analysed alongside serum sST2 and IL-33 levels at 13 months and asthma diagnoses at 7 years (PMID 38566447). Among two ST2 SNPs (rs1041973, rs13408661) and three IL-33 SNPs (rs1342326, rs12551256, rs12551268) examined, children carrying variants of rs12551268 were less often diagnosed with asthma by age 7. However, the authors explicitly note that these differences were not statistically significant, a limitation expected in a cohort of 146 children.

The biological plausibility for protective IL33 intronic variants is strong. Smith et al. 2017 (PMID 28273074) demonstrated that the rare IL33 splice-LOF variant rs146597587-C reduces total IL33 mRNA by 40% and protects against asthma with OR 0.47 in over 6,400 cases. If rs12551268 influences IL33 expression even modestly in the same direction, the mechanism is identical: less IL-33 reaching mast cells, ILC2s, and eosinophils means a quieter type-2 alarm response to airway challenge.

Critically, the evidence remains at the emerging level. One birth cohort study of 146 children, with a non-significant trend, is insufficient to establish the A allele as protective with confidence. Larger GWAS and functional studies are needed to determine whether this variant acts through gene regulation, and if so, how large the effect is. The IL33 locus is densely studied in asthma genetics; this variant has not appeared in any published GWAS Catalog entry or large consortium GWAS.

Practical Actions

Because the evidence is not statistically significant and the study was small, no strong personalised interventions can be recommended based solely on rs12551268 genotype. The protective trend is consistent with a biologically coherent mechanism, but caution is warranted in interpreting an emerging signal.

For C-allele homozygotes (the common genotype, ~52% of Europeans), the full complement of IL-33 signalling is unmodified at this locus — the same IL-33 pathway considerations that apply to the general population apply here. Other IL33 and IL1RL1 variants in your profile (such as rs992969 for the major regulatory signal) provide better-established guidance for actionable steps.

Interactions

rs12551268 exists within the same IL33 locus as the well-characterised risk variant rs992969 and the rare protective LOF variant rs146597587. The ST2 receptor side of the same signalling axis is captured by rs13408661 and rs1041973 (IL1RL1). Together, these variants describe the full IL-33/ST2 pathway from ligand expression to receptor density. If rs992969 and rs12551268 are on different haplotypes, their effects on IL33 expression may partially offset or compound depending on the specific combination — though no published data model this interaction.